Aptus Endosystems

About Aptus Endosystems

Aptus Endosystems, Inc. was a privately held medical device company established in 2002, with its headquarters in Sunnyvale, California. The firm specialized in developing and manufacturing advanced technologies for endovascular aneurysm repair (EVAR) and thoracic endovascular aneurysm repair (TEVAR). The company's focus was on addressing the market for abdominal aortic aneurysms (AAA), a life-threatening condition affecting an estimated 1.5 million Americans. The business model centered on providing physicians with tools that combined the minimally invasive benefits of EVAR with the durability and control of traditional open surgery.

The company's flagship product was the Heli-FX™ Aortic Securement System, an innovative helical anchor technology designed to provide independent fixation for endografts. This system allowed physicians to secure a stent graft to the aortic wall, mimicking the effect of hand-suturing performed during open surgery. The goal was to improve long-term outcomes by preventing stent graft migration and endoleaks, which are known complications of EVAR procedures, particularly in patients with complex anatomies. The system included components such as the Heli-FX Guide, a disposable applier, and cassettes containing the EndoAnchors. The Heli-FX systems received CE Mark approval in Europe and 510(k) clearance from the U.S. Food and Drug Administration (FDA), making them commercially available in both markets. The company also developed the TourGuide Steerable Sheath to facilitate the delivery of vascular products in challenging anatomical situations.

Throughout its history, Aptus Endosystems achieved several key milestones. It raised significant venture capital, with funding rounds totaling at least $70 million from investors including U.S. Venture Partners, Longitude Capital, and Baird Capital. Under the leadership of CEOs like Jeff Elkins and later James Reinstein, the company secured FDA clearance for its Heli-FX system for AAA in 2011 and for TAA in 2012. Jeff Elkins, who served as CEO and COO, had an extensive background in the endovascular field, having led development and commercialization at companies like World Medical Corp. and FlowMedica, both of which were also acquired. This journey culminated in a major strategic achievement on June 19, 2015, when Medtronic plc acquired the assets of Aptus Endosystems for approximately $110 million. The acquisition integrated Aptus's EndoAnchor technology into Medtronic's aortic and peripheral vascular division, validating the technology's mission to provide durable solutions for complex aortic disease.